The most notable antibody that targets ROR1 and blocks Wnt5a binding is Cirmtuzumab, which shows good outcome in ibrutinib resistant MCL and RR CLL. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.